CMPX
Compass Therapeutics, Inc.
$2.07
+0.14
(+7.25%)
Mkt Cap
286.25M
Volume
5,919,492
52W Range
1.61-6.88
Sector
Healthcare
Beta
0.67
EPS (TTM)
-0.43
P/E Ratio
-12.74
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 850,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (66.49M) | (49.38M) | (42.49M) | (39.23M) | (82.18M) | (29.50M) | (34.74M) | (38.29M) |
| EPS | -0.42 | -0.36 | -0.33 | -0.35 | -1.31 | -0.52 | -0.67 | -7.66 |
| Free Cash Flow | (49.17M) | (44.90M) | (40.65M) | (34.34M) | (21.23M) | (26.91M) | (32.21M) | (35.70M) |
| FCF / Share | -0.31 | -0.33 | -0.32 | -0.33 | -0.34 | -0.48 | -0.62 | -7.14 |
| Operating CF | (49.14M) | (44.85M) | (40.62M) | (34.12M) | (19.67M) | (26.80M) | (31.74M) | (33.68M) |
| Total Assets | 219.59M | 140.40M | 156.88M | 199.65M | 153.76M | 51.91M | 30.38M | 64.62M |
| Total Debt | 9.83M | 6.63M | 1.73M | 2.94M | 4.04M | 9.33M | 14.87M | 14.75M |
| Cash & Equiv | 30.64M | 43.48M | 24.23M | 34.95M | 144.51M | 47.08M | 25.30M | 57.51M |
| Book Value | 196.79M | 125.23M | 148.54M | 181.64M | 140.08M | 39.95M | (118.60M) | (84.77M) |
| Return on Equity | -0.34 | -0.39 | -0.29 | -0.22 | -0.59 | -0.74 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 850,000 | 0 | 0 | 0 | 0 |
| Net Income | (18.32M) | (15.72M) | (14.26M) | (19.88M) | (16.63M) | (15.03M) | (10.48M) | (13.08M) | (10.79M) | (13.41M) | (9.96M) | (11.28M) |
| EPS | -0.10 | -0.09 | -0.10 | -0.14 | -0.12 | -0.11 | -0.08 | -0.10 | -0.08 | -0.11 | -0.08 | -0.09 |
| Free Cash Flow | (17.35M) | (13.25M) | (10.86M) | (11.83M) | (13.23M) | (9.16M) | (11.10M) | (10.75M) | (13.89M) | (12.36M) | (5.93M) | (10.12M) |
| FCF / Share | -0.09 | -0.07 | -0.08 | -0.09 | -0.10 | -0.07 | -0.08 | -0.08 | -0.10 | -0.10 | -0.05 | -0.08 |
| Operating CF | (17.27M) | (13.25M) | (10.85M) | (11.83M) | (13.21M) | (9.16M) | (11.05M) | (10.75M) | (13.89M) | (12.35M) | (5.92M) | (10.11M) |
| Total Assets | 205.17M | 219.59M | 231.26M | 116.70M | 131.45M | 140.40M | 149.15M | 155.61M | 161.14M | 156.88M | 170.04M | 179.18M |
| Total Debt | 9.79M | 9.83M | 9.87M | 9.90M | 6.38M | 6.63M | 6.88M | 1.09M | 1.41M | 1.73M | 2.04M | 2.34M |
| Cash & Equiv | 55.17M | 30.64M | 46.21M | 22.86M | 41.05M | 43.48M | 36.80M | 19.40M | 23.67M | 24.23M | 30.43M | 19.28M |
| Book Value | 186.47M | 196.79M | 209.61M | 93.21M | 110.28M | 125.23M | 138.40M | 146.10M | 157.06M | 148.54M | 160.04M | 168.29M |
| Return on Equity | -0.10 | -0.08 | -0.07 | -0.21 | -0.15 | -0.12 | -0.08 | -0.09 | -0.07 | -0.09 | -0.06 | -0.07 |
CMPX News
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics to Participate in Upcoming May Investor Events
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update